BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36494694)

  • 21. Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.
    Jalali S; Price-Troska T; Paludo J; Villasboas J; Kim HJ; Yang ZZ; Novak AJ; Ansell SM
    Blood Adv; 2018 Aug; 2(15):1985-1997. PubMed ID: 30104397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.
    Muz B; de la Puente P; Azab F; Ghobrial IM; Azab AK
    Mol Cancer Res; 2015 Feb; 13(2):263-72. PubMed ID: 25232031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.
    Elsawa SF; Novak AJ; Ziesmer SC; Almada LL; Hodge LS; Grote DM; Witzig TE; Fernandez-Zapico ME; Ansell SM
    Blood; 2011 Nov; 118(20):5540-9. PubMed ID: 21921047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1.
    Hodge LS; Novak AJ; Grote DM; Braggio E; Ketterling RP; Manske MK; Price Troska TL; Ziesmer SC; Fonseca R; Witzig TE; Morice WG; Gertz MA; Ansell SM
    Blood; 2011 May; 117(19):e190-7. PubMed ID: 21415268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.
    Hunter ZR; Xu L; Yang G; Tsakmaklis N; Vos JM; Liu X; Chen J; Manning RJ; Chen JG; Brodsky P; Patterson CJ; Gustine J; Dubeau T; Castillo JJ; Anderson KC; Munshi NM; Treon SP
    Blood; 2016 Aug; 128(6):827-38. PubMed ID: 27301862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation.
    Shrimpton J; Care MA; Carmichael J; Walker K; Evans P; Evans C; de Tute R; Owen R; Tooze RM; Doody GM
    Blood Adv; 2020 Jun; 4(12):2821-2836. PubMed ID: 32574366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Kobayashi H; Asada N; Egusa Y; Ikeda T; Sakamoto M; Abe M; Ennishi D; Sakata M; Takaki A; Kawahara S; Meguri Y; Nishimori H; Fujii N; Matsuoka KI; Sato Y; Yoshino T; Maeda Y
    Int J Hematol; 2021 Sep; 114(3):401-407. PubMed ID: 33907976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.
    Wang L; Tang J; Feng J; Huang Y; Cheng Y; Xu H; Miao Y
    Front Immunol; 2022; 13():1001482. PubMed ID: 36325357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88.
    Sacco A; Federico C; Giacomini A; Caprio C; Maccarinelli F; Todoerti K; Favasuli V; Anastasia A; Motta M; Russo D; Rossi G; Bozza N; Castelli R; Neri A; Ronca R; Cattaneo C; Tucci A; Mor M; Presta M; Roccaro AM
    Blood; 2021 May; 137(18):2495-2508. PubMed ID: 33197938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The bone marrow niche in Waldenström's macroglobulinemia.
    Ghobrial IM; Zhang Y; Liu Y; Ngo H; Azab F; Sacco A; Azab A; Maiso P; Morgan B; Quang P; Issa G; Roccaro A
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):118-20. PubMed ID: 21454209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia.
    Leleu X; Hunter ZR; Xu L; Roccaro AM; Moreau AS; Santos DD; Hatjiharissi E; Bakthavachalam V; Adamia S; Ho AW; Soumerai J; Patterson CJ; Manning RJ; Hamilton S; Verselis S; Fox E; Carrasco R; Ghobrial IM; Treon SP
    Br J Haematol; 2009 Apr; 145(1):59-63. PubMed ID: 19220283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extramedullary Waldenström macroglobulinemia.
    Banwait R; Aljawai Y; Cappuccio J; McDiarmid S; Morgan EA; Leblebjian H; Roccaro AM; Laubach J; Castillo JJ; Paba-Prada C; Treon S; Redd R; Weller E; Ghobrial IM
    Am J Hematol; 2015 Feb; 90(2):100-4. PubMed ID: 25349134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Approaches in Waldenström Macroglobulinemia.
    Spinner MA; Varma G; Advani RH
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):875-890. PubMed ID: 30190025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience.
    Palomba ML; Qualls D; Monette S; Sethi S; Dogan A; Roshal M; Senechal B; Wang X; Rivière I; Sadelain M; Brentjens RJ; Park JH; Smith EL
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35173030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of subpopulation lacking both B-cell and plasma cell markers in Waldenstrom macroglobulinemia cell line.
    Wada N; Zhan M; Hori Y; Honma K; Ikeda J; Morii E
    Lab Invest; 2014 Jan; 94(1):79-88. PubMed ID: 24189269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
    Azab AK; Azab F; Quang P; Maiso P; Sacco A; Ngo HT; Liu Y; Zhang Y; Morgan BL; Roccaro AM; Ghobrial IM
    Clin Cancer Res; 2011 Jul; 17(13):4389-99. PubMed ID: 21521775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
    Eleutherakis-Papaiakovou E; Kastritis E; Gavriatopoulou M; Christoulas D; Roussou M; Ntanasis-Stathopoulos I; Kanellias N; Papatheodorou A; Dimopoulos MA; Terpos E
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):431-437. PubMed ID: 29685422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.
    Amaador K; Vos JMI; Pals ST; Kraan W; Dobber JA; Minnema MC; Koene HR; de Bruin PC; Zwinderman AH; Kersten MJ
    Leuk Lymphoma; 2022 May; 63(5):1070-1079. PubMed ID: 34961399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia.
    Gayet M; Leymarie V; Derouault P; Guérin E; Vaidié J; Pascal V; Boulin M; Dmytruk N; Chauzeix J; Trimoreau F; Gachard N; Feuillard J; Rizzo D
    Cytometry B Clin Cytom; 2022 Jan; 102(1):62-69. PubMed ID: 33634586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Rare Case of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma with Light Chain Discrepancy between B Lymphocyte Population and Serum Paraprotein.
    Kim HJ; Hur M; Kim H; Moon HW; Yun YM; Kim SY; Lee MH
    Ann Clin Lab Sci; 2015; 45(5):593-7. PubMed ID: 26586715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.